ORLANDO, Fla. and DUBLIN, Jan. 8, 2015 /PRNewswire/ -- Immune Therapeutics Inc. (OTC:BB IMUN) – The Jack Brewer Foundation (JBF Worldwide) and Immune Therapeutics, Inc. announced today a first-of-its-kind donation program to improve access to treatment to prevent cervical cancer that until now has been unavailable to the women of Malawi, Africa.
Cervical cancer accounts for approximately 45% of all diagnosed cancer cases in Malawi, and of the 2,300 women diagnosed with cervical cancer each year in Malawi approximately 1,600 of those cases will result in death. In fact, 90% of Africa offers little or no access to oncology care.
The program is designed to deliver a preventive and simple procedure that can be performed in a clinic setting without the use of a laboratory and further allows for immediate treatment of any precancerous lesions utilizing the Wallach LL100 Cryosurgical systems. The program initially entails the donation of multiple units of these systems to Queen Elizabeth Central Hospital and several clinics throughout Malawi.
Although cervical cancer is readily prevented via screening, early detection and treatment of precancerous lesions, most of the eligible women of reproductive health in Africa have never been screened. "It is time to develop programs for the prevention, early detection, treatment, and palliation of cancer sufferers in Africa," said His Excellency Ambassador Jack Brewer, Founder and Executive Director of The Jack Brewer Foundation. "It is our hope that this innovative donation program will be the first step in sparking further collaborative action across sub-Saharan Africa in our ongoing quest to improve global health."
"This program has the potential to revolutionize cervical cancer prevention efforts in emerging nations with limited resources because it eliminates the need for laboratories, does not require transportation of specimens and provides immediate test results," explained Noreen Griffin, CEO of Immune Therapeutics. "Medical providers in many different capacities can perform this procedure – generalist physicians, gynecologists, nurses and midwives – and The Wallach LL100 Cryosurgical system allows women access to screening and treatment in their own communities."
"Our goal here is to provide early intervention and therefore achieve a reduction in invasive cervical cancer (ICC) mortality in Malawi as well as other African Countries," Ambassador Brewer noted. "The donation program is part of our longstanding commitment by JBF Worldwide and our dedicated partners at Immune Therapeutics and CareMed Pharmaceutical Services to improve access to better health care for women."
The Malawi donation will be highlighted today at the United Nations headquarters in New York during the Reelcause launch event where The Jack Brewer Foundation will showcase their projects on a new innovative crowdfunding platform. All parties are looking forward to using donations to fund ongoing bridging trials as approved by local authorities for HIV/AIDS and cancer immediately in Malawi and Nigeria as well as through ongoing work in the United States.
About The Jack Brewer Foundation
Jack Brewer, five-year National Football League (NFL) veteran and founder/CEO of The Brewer Group, Inc., established The Jack Brewer Foundation (JBF Worldwide) to empower women and children living in impoverished and underdeveloped communities by enabling food security; promoting access to education and cultural exchanges; assisting in medical aid and disaster relief; and building peace. JBF Worldwide uses sport as a catalyst to provide resources and opportunities to the world's most underserved populations and actively works to "Empower From Within." For more information, please visit www.jbfworldwide.org or follow them on Twitter, Facebook, Instagram and Pinterest.
About Immune Therapeutics
Immune Therapeutics ("the Company") is a biotechnology company working to combat chronic, life-threatening diseases through the activation and modulation of the body's immune system using our patented immunotherapy. The Company's products and immunotherapy technologies are designed to harness the power of the immune system to improve the treatment of cancer, infections such as HIV/AIDS, chronic inflammatory diseases, and autoimmune diseases.
The Company's proprietary technology, therapies and patents include the treatment of a wide range of cancers. The Company's most advanced clinical programs involve immunotherapy with met-enkephalin ("MENK") (sometimes referred to as opioid growth factor) and its Low Dose Naltrexone product ("LDN") or Lodonal™, which have been shown to stimulate the immune system even in patients with advanced cancer.
Even though Management considers any condition that results in altered-immune response a target for investigation, the Company will most likely pursue additional investigations for MENK and LDN as valuable candidates in the treatment of autoimmune states such as rheumatoid arthritis and multiple sclerosis; as an adjunct in cancer patients undergoing chemotherapy, radiation treatments or surgery; and as a complement to antibiotics in the treatment of a variety of infectious diseases, including patients with HIV/AIDS, in combination with retroviral drug therapy.
About Airmed Biopharma Limited
Airmed Biopharma Limited, a wholly owned Irish company, is the pharmaceutical sales division of the Company. Airmed Biopharma Limited is responsible for servicing sales orders for Lodonal™ where the Company has received sales approval in Latin America and Africa.
Cautionary Note Regarding Forward-Looking Statements
This document includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements about the plans, objectives, expectations and intentions of the Company, including the benefits of the spin-off of Cytocom Inc. from the Company, and other statements that are not historical facts. These statements are based on the current expectations and beliefs of our management and are subject to uncertainty and changes in circumstances. We caution readers that any forward-looking information is not a guarantee of future performance and that actual results may vary materially from those expressed or implied by the statements herein due to the conditions to the consummation of the spin-off of Cytocom Inc. from the Company, and changes in economic, business, competitive, technological, strategic and/or regulatory factors, as well as other factors affecting the operation of the other businesses of the Company and Cytocom Inc. More detailed information about these factors may be found in our filings with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K in the sections entitled "Cautionary Note Regarding Forward-Looking Statements" and "Risk Factors." Various other factors could cause actual results to differ from those set forth in the forward-looking statements, including, without limitation, the risk that the anticipated benefits from the spin-off may not be fully realized or may take longer to realize than expected. We are under no obligation to, and expressly disclaim any such obligation to, update or alter our forward-looking statements, whether as a result of new information, future events, or otherwise. The Company undertakes no obligation to publicly release any revisions to such forward-looking statements to reflect events or circumstances after the date hereof. For further information, please see http://www.immunetherapeutics.com.
Contact: Dennis S. Dobson
President and CEO
Dobson Media Group and
International Investor Relations Services Inc.
SOURCE Immune Therapeutics Inc.